BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+57.51%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$3.59B
AUM Growth
+$3.59B
(+31%)
Cap. Flow
-$161M
Cap. Flow
% of AUM
-4.48%
Top 10 Holdings %
Top 10 Hldgs %
60.96%
Holding
76
New
4
Increased
8
Reduced
4
Closed
9
Top Buys
| 1 |
IDEAYA Biosciences
IDYA
|
$75.9M |
| 2 |
Revolution Medicines
RVMD
|
$34.8M |
| 3 |
Janux Therapeutics
JANX
|
$29.9M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$11.7M |
| 5 |
ALLK
Allakos
ALLK
|
$11.3M |
Top Sells
| 1 |
Verastem
VSTM
|
$129M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$45.3M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$44M |
| 4 |
Immunovant
IMVT
|
$39.7M |
| 5 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$37M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $1.11B | 30.92% | 21,751,284 | – | – |
|
|
2
Revolution Medicines
RVMD
$7.1B
| $167M | 4.66% | 6,255,588 +1,300,000 | +26% | +$34.8M |
|
3
Axsome Therapeutics
AXSM
$6.05B
| $153M | 4.27% | 2,131,100 | – | – |
|
|
4
IDEAYA Biosciences
IDYA
$2.15B
| $134M | 3.72% | 5,683,489 +3,228,400 | +131% | +$75.9M |
|
|
5
Ionis Pharmaceuticals
IONS
$6.79B
| $117M | 3.25% | 2,846,015 +285,254 | +11% | +$11.7M |
|
6
GH Research
GHRS
$837M
| $110M | 3.07% | 9,275,158 | – | – |
|
7
Kymera Therapeutics
KYMR
$2.95B
| $109M | 3.04% | 4,739,004 | – | – |
|
8
Protagonist Therapeutics
PTGX
$3.67B
| $104M | 2.91% | 3,775,900 | – | – |
|
|
PNT
9
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $95.7M | 2.67% | 10,563,748 | – | – |
|
10
Galapagos
GLPG
$2.07B
| $88M | 2.45% | 2,165,109 | – | – |
|
11
Repare Therapeutics
RPTX
$71.7M
| $87.7M | 2.45% | 8,291,988 | – | – |
|
12
Structure Therapeutics
GPCR
$1.11B
| $72.7M | 2.03% | 1,750,000 | – | – |
|
13
4D Molecular Therapeutics
FDMT
$288M
| $72.4M | 2.02% | 4,007,413 | – | – |
|
14
Kura Oncology
KURA
$686M
| $71.2M | 1.98% | 6,730,983 | – | – |
|
15
Xenon Pharmaceuticals
XENE
$2.98B
| $70.4M | 1.96% | 1,827,958 | – | – |
|
16
Olema Pharmaceuticals
OLMA
$375M
| $68.7M | 1.92% | 7,611,503 | – | – |
|
17
Xoma
XOMA
$392M
| $68.6M | 1.91% | 3,633,743 | – | – |
|
|
CNTA
18
Centessa Pharmaceuticals
CNTA
$2.25B
| $58.3M | 1.63% | 9,423,215 | – | – |
|
19
Zymeworks
ZYME
$1.12B
| $50.7M | 1.41% | 5,870,000 | – | – |
|
20
Replimune Group
REPL
$422M
| $49.8M | 1.39% | 2,143,036 | – | – |
|
|
21
Janux Therapeutics
JANX
$1.37B
| $48.7M | 1.36% | 4,106,945 +2,521,268 | +159% | +$29.9M |
|
22
Tyra Biosciences
TYRA
$675M
| $46.7M | 1.3% | 2,739,595 -500,000 | -15% | -$8.52M |
|
23
Lexicon Pharmaceuticals
LXRX
$400M
| $45.8M | 1.28% | 19,995,332 +3,846,153 | +24% | +$8.81M |
|
24
Merus
MRUS
$4.98B
| $42.2M | 1.18% | 1,602,420 -1,376,000 | -46% | -$36.2M |
|
25
Relay Therapeutics
RLAY
$619M
| $39.2M | 1.09% | 3,120,521 | – | – |
|